Joshua Hare, MD, FAAC, highlights stem cell therapy for female sexual dysfunction

In this Contemporary OB/GYN video interview, Joshua Hare, MD, FACC, discusses the prevalence of female sexual dysfunction (FSD), the challenges associated with its treatment, and emerging research exploring the potential role of mesenchymal stem cells in improving sexual quality of life among older women.

Hare emphasizes that FSD is highly prevalent and becomes more common with age, particularly after menopause. An estimated 40% of postmenopausal women experience some form of FSD, making it a significant and often underrecognized issue. Beyond its frequency, Hare underscores the profound impact FSD can have on quality of life, affecting emotional well-being, relationships, and overall life satisfaction.

Treating FSD remains challenging, largely because it has historically been understudied. Hare notes that female sexuality—especially among older, postmenopausal women—has been partially neglected in clinical research. Currently, only 1 drug is approved for the condition, and while some urologists and gynecologists specialize in FSD, they represent a relatively small clinical community. This lack of therapeutic options highlights the importance of new research avenues and potential breakthroughs.

Hare then explains how findings related to mesenchymal stem cells emerged from broader research on healthy aging and “health span,” defined as the portion of life spent in good health rather than simply longevity. Although life expectancy has increased in the United States and other Western countries, many individuals spend their final decade or more experiencing poor physical, mental, and functional health. Longevron has been studying laromestrocel, a mesenchymal stem cell product, as a potential therapy to improve health span in older adults with frailty or age-related decline.

As part of these studies, researchers included questionnaires assessing sexual quality of life, recognizing sexuality as a key component of human health and relationships. Unexpectedly, women reported improved sexual satisfaction within 3 to 6 months following intravenous stem cell infusion. While it remains unclear whether these improvements are directly related to sexual function or reflect broader enhancements in overall well-being, the findings were consistent and notable.

In addition to reported improvements in sexual quality of life, participants experienced better physical functioning, increased mobility, and improved cardiovascular markers. Hare explains that a newly issued use patent protects the application of laromestrocel for treating diminished sexual function in women aged 60 to 90 years. He concludes by clarifying that FDA approval is still being pursued and that ongoing research continues to explore multiple indications for stem cell therapy in aging populations.

No relevant disclosures.

Reference

Longeveron granted US patent for method of treating female sexual dysfunction using its proprietary stem cell therapy. Longeveron. December 17, 2025. Accessed December 23, 2025. https://finance.yahoo.com/news/longeveron-granted-u-patent-method-141500775.html?guccounter=1